UY24286A1 - Nuevo proceso para la producción de una sal ácida calcica amorfa - Google Patents
Nuevo proceso para la producción de una sal ácida calcica amorfaInfo
- Publication number
- UY24286A1 UY24286A1 UY24286A UY24286A UY24286A1 UY 24286 A1 UY24286 A1 UY 24286A1 UY 24286 A UY24286 A UY 24286A UY 24286 A UY24286 A UY 24286A UY 24286 A1 UY24286 A1 UY 24286A1
- Authority
- UY
- Uruguay
- Prior art keywords
- calcica
- production
- solvent
- acid salt
- new process
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000002253 acid Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 abstract 4
- 239000002904 solvent Substances 0.000 abstract 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 abstract 3
- 229960005370 atorvastatin Drugs 0.000 abstract 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 2
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000006260 foam Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000010907 mechanical stirring Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000001694 spray drying Methods 0.000 abstract 1
- 238000001291 vacuum drying Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US145395P | 1995-07-17 | 1995-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY24286A1 true UY24286A1 (es) | 1997-01-17 |
Family
ID=21696097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY24286A UY24286A1 (es) | 1995-07-17 | 1996-07-17 | Nuevo proceso para la producción de una sal ácida calcica amorfa |
Country Status (37)
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| IN191236B (enExample) * | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
| US6646133B1 (en) | 2000-10-17 | 2003-11-11 | Egis Gyogyszergyar Rt. | Process for the preparation of amorphous atorvastatin calcium |
| HU226640B1 (en) * | 1999-10-18 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Process for producing amorphous atorvastatin calcium salt |
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
| IL155890A0 (en) * | 2000-11-16 | 2003-12-23 | Teva Pharma | HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-beta,delta-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE |
| US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| ES2319870T3 (es) | 2000-12-27 | 2009-05-14 | Teva Pharmaceutical Industries Limited | Formas cristalinas de atorvastatina. |
| WO2002057228A1 (en) * | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
| WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
| SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
| IN190564B (enExample) * | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
| HUP0400381A2 (hu) | 2001-06-29 | 2004-09-28 | Warner-Lambert Company Llc | [R-(R*,R*)]-2-(4fluorfenil)-béta, delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)karbonil]-1H-pirrol-1-heptánsav 2:1 arányú kalciumsójának (atorvasztatin) kristályos formái |
| US7361772B2 (en) | 2001-08-16 | 2008-04-22 | Biocon Limited | Process for the production of atorvastatin calcium |
| AU2001284385A1 (en) | 2001-08-31 | 2003-03-10 | Morepen Laboratories Ltd. | An improved process for the preparation of amorphous atorvastatin calcium salt (2:1) |
| UA77990C2 (en) * | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
| CZ296967B6 (cs) | 2002-02-01 | 2006-08-16 | Zentiva, A.S. | Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) |
| RU2309141C2 (ru) * | 2002-03-18 | 2007-10-27 | Байокон Лимитид | АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
| JP4308021B2 (ja) | 2002-03-18 | 2009-08-05 | バイオコン・リミテッド | 望ましい粒子サイズのアモルファスＨＭＧ−ＣｏＡレダクターゼ阻害剤 |
| ITMI20020907A1 (it) * | 2002-04-29 | 2003-10-29 | Chemi Spa | Processo di preparazione della forma amorfa del sale di calcio della atorvastatina |
| AU2002356423A1 (en) * | 2002-05-28 | 2003-12-12 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
| US7179942B2 (en) | 2002-07-05 | 2007-02-20 | Bicon Limited | Halo-substituted active methylene compounds |
| AU2002330735A1 (en) * | 2002-09-03 | 2004-03-29 | Morepen Laboratories Limited | Atorvastatin calcium form vi or hydrates thereof |
| EA013500B1 (ru) * | 2003-04-11 | 2010-06-30 | Лек Фармасьютиклз Д.Д. | Способ получения аморфной кальциевой соли аторвастатина |
| US7232920B2 (en) | 2003-04-22 | 2007-06-19 | Biocon | Process for stereoselective reduction of β-ketoesters |
| US7790197B2 (en) * | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| US7655692B2 (en) * | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| AU2003272080A1 (en) | 2003-09-18 | 2005-04-06 | Biocon Limited | Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate |
| CA2456430A1 (en) * | 2004-01-28 | 2005-07-28 | Brantford Chemicals Inc. | Improved process for the preparation of amorphous atorvastatin calcium |
| CZ298382B6 (cs) * | 2004-03-10 | 2007-09-12 | Zentiva, A. S. | Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace |
| CA2666359A1 (en) | 2004-03-17 | 2005-10-06 | Yatendra Kumar | Process for the production of atorvastatin calcium in amorphous form |
| US7875731B2 (en) | 2004-05-05 | 2011-01-25 | Pfizer Inc. | Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid |
| AU2005263550C1 (en) * | 2004-07-16 | 2013-01-17 | Lek Pharmaceuticals D.D. | Oxidative degradation products of atorvastatin calcium |
| WO2006021969A1 (en) | 2004-08-27 | 2006-03-02 | Biocon Limited | Process for atorvastatin calcium amorphous |
| KR20070106680A (ko) * | 2004-09-30 | 2007-11-05 | 닥터 레디스 레보러터리즈 리미티드 | 비정질 아토르바스타틴 칼슘 |
| CA2582087A1 (en) * | 2004-10-18 | 2006-04-27 | Teva Pharmaceutical Industries Ltd. | Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent |
| EP1807055A1 (en) * | 2004-10-28 | 2007-07-18 | Warner-Lambert Company LLC | Process for forming amorphous atorvastatin |
| AU2005305460B2 (en) | 2004-11-22 | 2011-04-21 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
| JP2008521878A (ja) * | 2004-12-02 | 2008-06-26 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 非晶質アトルバスタチンの医薬組成物及びその製造のための方法 |
| US20080108664A1 (en) | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
| EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
| JP2007231018A (ja) * | 2006-03-01 | 2007-09-13 | Teva Pharmaceutical Industries Ltd | アトルバスタチンヘミカルシウムの結晶形の調製方法 |
| US20100113802A1 (en) * | 2006-11-02 | 2010-05-06 | Cadila Pharmaceuticals Limited | Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate |
| US7834195B2 (en) | 2007-01-24 | 2010-11-16 | Apotex Pharmachem Inc. | Atorvastatin calcium propylene glycol solvates |
| EP2185527A2 (en) * | 2007-07-11 | 2010-05-19 | Actavis Group PTC EHF | Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium |
| US20090124817A1 (en) * | 2007-11-09 | 2009-05-14 | The Industry & Academic Cooperation In Chungnam National University | Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles |
| EP2075246A1 (en) | 2007-12-27 | 2009-07-01 | M. J. Institute of Research | A process for preparation of amorphous form of atorvastatin hemi-calcium salt |
| WO2010066846A2 (en) * | 2008-12-11 | 2010-06-17 | Dsm Ip Assets B.V. | Method for the isolation of atorvastatin |
| EP2327682A1 (en) | 2009-10-29 | 2011-06-01 | KRKA, D.D., Novo Mesto | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates |
| SI2373609T1 (sl) | 2008-12-19 | 2013-12-31 | Krka, D.D., Novo Mesto | Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov |
| CZ201039A3 (cs) | 2010-01-19 | 2011-07-27 | Zentiva, K. S | Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US5216174A (en) | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| US5124482A (en) | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
| US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5149837A (en) | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5248793A (en) | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5103024A (en) | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5155251A (en) | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
| US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| SI1148049T1 (en) | 1995-07-17 | 2005-02-28 | Warner-Lambert Company | Crystalline R-(R*,R*)$-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl -1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
-
1996
- 1996-07-03 HR HR960312A patent/HRP960312B1/xx not_active IP Right Cessation
- 1996-07-16 AT AT96924553T patent/ATE199542T1/de not_active IP Right Cessation
- 1996-07-16 DE DE69611999T patent/DE69611999T2/de not_active Revoked
- 1996-07-16 CN CN96195631A patent/CN1087289C/zh not_active Expired - Lifetime
- 1996-07-16 CZ CZ1998122A patent/CZ289421B6/cs not_active IP Right Cessation
- 1996-07-16 EA EA199800128A patent/EA000625B1/ru not_active IP Right Cessation
- 1996-07-16 IL IL12216196A patent/IL122161A/xx not_active IP Right Cessation
- 1996-07-16 AR ARP960103599A patent/AR002849A1/es not_active Application Discontinuation
- 1996-07-16 PT PT96924553T patent/PT839132E/pt unknown
- 1996-07-16 CA CA002220455A patent/CA2220455C/en not_active Expired - Lifetime
- 1996-07-16 SI SI9630284T patent/SI0839132T1/xx unknown
- 1996-07-16 PL PL324463A patent/PL191017B1/pl unknown
- 1996-07-16 WO PCT/US1996/011807 patent/WO1997003960A1/en not_active Ceased
- 1996-07-16 SK SK58-98A patent/SK283204B6/sk not_active IP Right Cessation
- 1996-07-16 NZ NZ313008A patent/NZ313008A/xx not_active IP Right Cessation
- 1996-07-16 MX MX9708959A patent/MX9708959A/es unknown
- 1996-07-16 GE GEAP19964149A patent/GEP20002027B/en unknown
- 1996-07-16 BR BR9609714A patent/BR9609714A/pt not_active Application Discontinuation
- 1996-07-16 JP JP50681497A patent/JP4064459B2/ja not_active Expired - Lifetime
- 1996-07-16 KR KR10-1998-0700348A patent/KR100400805B1/ko not_active Expired - Lifetime
- 1996-07-16 RO RO98-00060A patent/RO120069B1/ro unknown
- 1996-07-16 UA UA98020823A patent/UA50743C2/uk unknown
- 1996-07-16 IN IN1579DE1996 patent/IN185276B/en unknown
- 1996-07-16 AU AU64978/96A patent/AU700794B2/en not_active Expired
- 1996-07-16 EE EE9700369A patent/EE03605B1/xx unknown
- 1996-07-16 EP EP96924553A patent/EP0839132B1/en not_active Revoked
- 1996-07-16 HU HU9903017A patent/HU220343B/hu unknown
- 1996-07-16 ES ES96924553T patent/ES2156997T3/es not_active Expired - Lifetime
- 1996-07-16 DK DK96924553T patent/DK0839132T5/da active
- 1996-07-17 UY UY24286A patent/UY24286A1/es not_active IP Right Cessation
- 1996-07-17 CO CO96037512A patent/CO4700441A1/es unknown
- 1996-07-17 ZA ZA9606043A patent/ZA966043B/xx unknown
- 1996-07-17 PE PE1996000541A patent/PE1698A1/es not_active IP Right Cessation
-
1998
- 1998-01-14 BG BG102188A patent/BG63631B1/bg unknown
- 1998-01-16 NO NO980209A patent/NO309322B1/no unknown
-
2000
- 2000-09-07 US US09/657,469 patent/US6274740B1/en not_active Expired - Lifetime
-
2001
- 2001-05-15 GR GR20010400710T patent/GR3035859T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY24286A1 (es) | Nuevo proceso para la producción de una sal ácida calcica amorfa | |
| DE59607301D1 (de) | Verfahren zur Herstellung von photopolymeren Hochdruckplatten | |
| DE3768869D1 (de) | Verfahren und anlage zur herstellung eines eine stapelung von trockenen steinen nachahmenden bauelementes. | |
| DE69512942D1 (de) | Verfahren zur Herstellung von Silber-Palladium Pulver durch Aerosol Zersetzung | |
| DE69615413D1 (de) | Vorrichtung zum Entfernen keramischen Schalenformmaterials von Gussstücken durch alkalisches Spritzen | |
| MY133511A (en) | Process for the production of amorphous atorvastatin calcium | |
| DE68920267D1 (de) | Verfahren zur Herstellung von einem durch Keramik verstärkten Verbundmaterial. | |
| DE69723918D1 (de) | Verfahren zur Umwandlung von organischen Abfällen in Werkstoffe | |
| DE69915403D1 (de) | Verfahren zur Herstellung von überbasischen Calciumsulfonat Detergentia | |
| AU3038989A (en) | Method for removal of organic solvents from aqueous process streams | |
| AR224377A1 (es) | Un proceso para el reordenamiento de tabaco expandido mediante una neblina acuosa | |
| IL149989A0 (en) | Method for decaying | |
| DE69718361D1 (de) | Verfahren zur Herstellung von Vorrichtungen zur gesteuerten Freisetzung | |
| DE69221398D1 (de) | Verfahren zur Herstellung von Kontaktwerkstoffen für Vakuumschalter | |
| ATE282032T1 (de) | Verfahren zur herstellung von isoflavonverbindungen | |
| DE69700191D1 (de) | Verfahren zur Herstellung von Nickelhydroxyd | |
| DE69710803D1 (de) | Verfahren zur Herstellung von geschlossenen Vesikeln durch Rehydratisierung von dehydratisierten Vesikeln | |
| ATE285826T1 (de) | Lösungsmittelextraktionsverfahren | |
| BR0017236A (pt) | Processo para remoção de contaminantes de flocos de rpet | |
| DE69016838D1 (de) | Verfahren zur Herstellung von organischen Estern. | |
| DE69817489D1 (de) | Verfahren zur Herstellung eines Betonproduktes | |
| DE59008305D1 (de) | Verfahren zur gleichzeitigen Gewinnung von reinem Benzol und reinem Toluol. | |
| DE3887605D1 (de) | Verfahren zur Herstellung eines Verbundmaterials. | |
| ES2142253B1 (es) | Procedimiento para la preparacion de un producto carnico, torre de prensado y equipo para la realizacion de dicho procedimiento. | |
| MX9302153A (es) | Proceso de secado por aspersion de la aminoguanidina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| VENC | Patent expired |
Effective date: 20160717 |